Costa-Gouveia Joana, Aínsa José A, Brodin Priscille, Lucía Ainhoa
University of Lille, CNRS, INSERM, University Hospital Center of Lille, Pasteur Institute of Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France.
Departamento de Microbiología (Facultad de Medicina), and BIFI, Universidad de Zaragoza, Zaragoza, Spain; Instituto de Investigación Sanitaria Aragón (IIS-Aragón), Zaragoza, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Drug Discov Today. 2017 Mar;22(3):600-607. doi: 10.1016/j.drudis.2017.01.011. Epub 2017 Jan 27.
Therapeutic approaches using nanoparticles are being successfully used in foods and in several fields of medicine, including infectious diseases. Regarding tuberculosis (TB) treatment, nanoparticles can be a useful strategy for two distinct applications: (i) for their intrinsic antimycobacterial activity; (ii) as vehicles for known antitubercular drugs to allow reduction of dose- and drug-associated side-effects and administration via user-friendly administration routes such as pulmonary or oral ones. Promising results were obtained in vitro and in animal Mycobacterium tuberculosis models and need now to be translated into clinical drug candidates. Such a prospect can provide an opportunity regarding the current limited therapeutic options for drug-resistant TB and the scarcity of novel antituberculosis drugs in the drug discovery pipeline.
使用纳米颗粒的治疗方法已成功应用于食品和包括传染病在内的多个医学领域。关于结核病（TB）治疗，纳米颗粒可用于两种不同的应用：（i）因其固有的抗分枝杆菌活性；（ii）作为已知抗结核药物的载体，以减少剂量和药物相关的副作用，并通过如肺部或口服等用户友好的给药途径进行给药。在体外和动物结核分枝杆菌模型中已取得了有前景的结果，现在需要将其转化为临床候选药物。对于目前耐药结核病治疗选择有限以及药物研发管道中新型抗结核药物稀缺的情况而言，这样的前景提供了一个机会。
